Last reviewed · How we verify
GLPG0634
At a glance
| Generic name | GLPG0634 |
|---|---|
| Also known as | GLPG0634 tablets |
| Sponsor | Galapagos NV |
| Modality | Small molecule |
| Phase | Phase 2 |
Approved indications
Common side effects
Key clinical trials
- Describing Treatment Patterns and Creating an Updated Treatment Flow in an Ulcerative Colitis Population
- A Study Evaluating the Effects of Filgotinib in Children and Teenagers With Ulcerative Colitis (PHASE3)
- A Study of Filgotinib 200 mg in Korean Participants With Moderately to Severely Active Ulcerative Colitis Under Routine Clinical Practice (PHASE4)
- Prospective Observational Study of Effectiveness and Safety of Filgotinib in Participants With Ulcerative Colitis (UC)
- Prospective Observational Study of Filgotinib in Participants With Rheumatoid Arthritis in France
- Study to Measure Filgotinib in the Blood of Children and Teenagers With Arthritis Taking Filgotinib (SCALESIA) (PHASE1)
- A Study Evaluating the Effect of Filgotinib in Participants With Active Axial Spondyloarthritis (PHASE3)
- A Study of Filgotinib in Korean Participants With Rheumatoid Arthritis (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- GLPG0634 CI brief — competitive landscape report
- GLPG0634 updates RSS · CI watch RSS
- Galapagos NV portfolio CI